search
Back to results

Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes (HOT-DM)

Primary Purpose

Hypertension, Obesity, Diabetes

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Temisartan
Amlodipine
Sponsored by
Third Military Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Abdominal obesity, Diabetes, Treatment

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Information Consent Signed
  • Aged 30~70 years
  • For whom without anti-hypertensive therapy in 2 weeks:140mmHg≤SBP<180mmHg,或90mmHg≤DBP<110mmHg. For whom with anti-hypertensive therapies in 2 weeks:SBP<180mmHg, 且DBP<110mmHg
  • Waist circumference higher than 90cm in men, 80cm in women
  • Diagnosed diabetes

Exclusion Criteria:

  • Grade 3 hypertension: SBP≥180mmHg, or DBP≥110mmHg
  • Waist circumference less than 90cm in men, 80cm in women
  • Known allergy or hypersensitivity to trial drugs
  • NYHA grade Ⅱ~Ⅳ heart failure, Myocardial infarction or cerebrovascular accident in 1 year preceding the trial
  • Acute infections, tumor, severe arrhythmia, mental disease, drug or alcohol abuse
  • History of hepatitis or cirrhosis
  • History of severe kidney disease
  • Pregnant, lactation
  • Enrolled in other trials in 3 months
  • Any obstacles of follow-up or compliance

Sites / Locations

  • The third hospital affiliated to the Third Military Medical University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Telmisartan Group

Amlodipine Group

Arm Description

Telmisartan intervention group

Amlodipine intervention group

Outcomes

Primary Outcome Measures

Blood Pressure
Metabolic profiles, including lipid profile and blood glucose

Secondary Outcome Measures

Abdominal fat assessed by CT
Obesity parameters, including waist circumference (WC) and body mass index (BMI)
Incidents of side effects between groups

Full Information

First Posted
February 17, 2009
Last Updated
December 15, 2013
Sponsor
Third Military Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT00847262
Brief Title
Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes
Acronym
HOT-DM
Official Title
Hypertension With Obesity Trial: Diabetes Mellitus Branch
Study Type
Interventional

2. Study Status

Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
June 2008 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
June 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Third Military Medical University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Recent studies have shown that obese people are more prone to high blood pressure. With the co-existence of obesity, hypertension and diabetes, patients were more susceptible to hyperlipidemia, coronary and cerebral atherosclerosis and peripheral vascular disease. Abdominal obesity has often accompanied by substantial accumulation of visceral fat, which increased secretion of many inflammatory mediators, cytokines and adipocytokines and played an important role in cardiovascular and metabolic disease. Some reports had shown that angiotensin II receptor blockers (ARB) may improve metabolic profiles in patients with diabetes or metabolic syndrome, in addition to its hypotensive effect. It has been reported that some ARB, such as telmisartan and candesartan, can prevent weight gain and high-fat-induced obesity in experimental animals. However, whether telmisartan intervention on improvement of fat deposition and other related metabolic profiles is better than a CCB drugs (amlodipine) in those obese hypertensive patients with diabetes, was still unknown.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Obesity, Diabetes
Keywords
Hypertension, Abdominal obesity, Diabetes, Treatment

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Telmisartan Group
Arm Type
Experimental
Arm Description
Telmisartan intervention group
Arm Title
Amlodipine Group
Arm Type
Active Comparator
Arm Description
Amlodipine intervention group
Intervention Type
Drug
Intervention Name(s)
Temisartan
Intervention Description
Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
Intervention Type
Drug
Intervention Name(s)
Amlodipine
Intervention Description
Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
Primary Outcome Measure Information:
Title
Blood Pressure
Time Frame
Baseline, 24 weeks(End of trial)
Title
Metabolic profiles, including lipid profile and blood glucose
Time Frame
Baseline, 24 weeks(End of trial)
Secondary Outcome Measure Information:
Title
Abdominal fat assessed by CT
Time Frame
Baseline, 24 weeks(End of trial)
Title
Obesity parameters, including waist circumference (WC) and body mass index (BMI)
Time Frame
Baseline, 24 weeks(End of trial)
Title
Incidents of side effects between groups
Time Frame
Baseline, 24 weeks(End of trial)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Information Consent Signed Aged 30~70 years For whom without anti-hypertensive therapy in 2 weeks:140mmHg≤SBP<180mmHg,或90mmHg≤DBP<110mmHg. For whom with anti-hypertensive therapies in 2 weeks:SBP<180mmHg, 且DBP<110mmHg Waist circumference higher than 90cm in men, 80cm in women Diagnosed diabetes Exclusion Criteria: Grade 3 hypertension: SBP≥180mmHg, or DBP≥110mmHg Waist circumference less than 90cm in men, 80cm in women Known allergy or hypersensitivity to trial drugs NYHA grade Ⅱ~Ⅳ heart failure, Myocardial infarction or cerebrovascular accident in 1 year preceding the trial Acute infections, tumor, severe arrhythmia, mental disease, drug or alcohol abuse History of hepatitis or cirrhosis History of severe kidney disease Pregnant, lactation Enrolled in other trials in 3 months Any obstacles of follow-up or compliance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhiming Zhu, MD, PhD
Organizational Affiliation
The third hospital affiliated to the Third Military Medical University. China
Official's Role
Principal Investigator
Facility Information:
Facility Name
The third hospital affiliated to the Third Military Medical University
City
Chongqing
ZIP/Postal Code
400042
Country
China

12. IPD Sharing Statement

Learn more about this trial

Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes

We'll reach out to this number within 24 hrs